We conclude that impaired glucose-induced generation of cAMP is an important determinant of defective insulin secretion after chronic palmitate exposure.
INTRODUCTION
There is a strong link between type 2 diabetes and obesity and the disease is often associated with increased plasma free fatty acid (FFA) concentrations (1, 2) . While acute exposure of insulin-secreting β-cells to saturated fatty acids, such as palmitate, stimulates insulin secretion (3, 4) , long-term palmitate exposure is associated with β-cell dysfunction, including reduction of glucose-stimulated insulin secretion (5) (6) (7) (8) (9) .
The mechanisms by which chronic palmitate exposure impairs insulin secretion are incompletely understood but probably involve multiple effects at different levels (9) .
For example, palmitate has been reported to cause alterations in β-cell metabolism (10) and ion channel activity (11) . The lipid has also been found to reduce insulin biosynthesis and to induce mitochondrial uncoupling, ceramide synthesis and ER stress, eventually leading to apoptotic cell death (7, (12) (13) (14) (15) . However, reduced insulin secretion after long-term exposure to fatty acids has been reported to occur before apparent signs of increased β-cell death, alterations of insulin synthesis, glucose metabolism, ATP-sensitive K + channel (K ATP channel) regulation or Ca 2+ signaling, suggesting that the secretion defect occurs at a late step in the exocytosis process (16) , not as a result of decreased release competence of the secretory vesicles, but because they become uncoupled from the sites of Ca 2+ entry (17) .
The depolarization-triggered entry of Ca 2+ through L-type voltage-dependent Ca 2+ channels is the final step in a chain of events by which glucose triggers insulin secretion (18, 19) . Apart from the triggering role of Ca
2+
, insulin secretion is markedly amplified by cAMP. While cAMP is known to mediate the insulinotropic effects of e.g. glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (20) , accumulating evidence indicate that cAMP elevation is also required for a normal insulin secretory response to glucose alone (21, 22) . In the present study we used various live-cell imaging techniques to investigate whether the reduced insulin response to glucose after chronic exposure to palmitate is associated with changes of β-cell cAMP signaling.
Technologies (Carlsbad, CA, USA). Plasmids and adenoviral vectors encoding a translocation biosensor for the cAMP concentration beneath the plasma membrane ( [cAMP] pm ) have previously been described (23) . The sensor consists of a truncated and membrane-anchored PKA regulatory RIIβ subunit tagged with CFP and a PKA catalytic Cα subunit tagged with YFP (24) . Insulin secretion dynamics was monitored using the PtdIns(3,4,5)P 3 translocation reporter GFP 4 -Grp1 (21) .
Islet and cell culture, transfection and palmitate treatment
Islets of Langerhans were isolated from C57Bl6J female mice as previously described (23 mmol/L nicotinamide, 10 mmol/L HEPES, 0.25 µg/ml Fungizone, 50 µg/ml gentamicin, 2 mmol/L glutamine, 10 g/ml ciprofloxacin, and 10% fetal calf serum.
Following isolation and purification both mouse and human islets were cultured for 1-4 days in RPMI 1640 medium containing 5.5 mmol/L glucose and supplemented with 10% fetal calf serum, 100 µg/ml penicillin, 100 µg/ml streptomycin and 1%
BSA. Palmitate (0.5 mmol/L) was present for 1 h or 48 h prior to the microscopy recordings. A 100 mmol/L stock solution of palmitate was prepared in 50% ethanol.
This solution was subsequently diluted in culture medium to a final concentration of 0.5 mmol/L and then allowed to complex with fatty acid-free BSA at 37°C. Control groups were exposed for the same period of time to media without palmitate, but otherwise with identical composition, including ethanol.
The islets were infected with adenovirus encoding GFP 4 -Grp1 or the cAMP biosensor using 10 5 fluorescent forming units/islet in culture medium as previously described (23) . After 1 hour incubation at 37 °C, the inoculum was removed and the islets were washed and further cultured for 20-24 h. Before microscopy recordings, the islets were incubated for 30 min at 37°C in experimental buffer containing 125 Insulin-secreting MIN6 β-cells of passages 17-30 (27) 
Batch measurements of insulin secretion
Control and palmitate-treated islets were preincubated in experimental buffer for 30 min at 37 °C. Groups of 10 islets were then transferred to the different test media and incubated for 30 min. After collection of supernatants the islets were sonicated for 10 s in acid ethanol to extract total insulin. The sample contents of insulin were 7 determined by an electrochemiluminescence immunoassay (Meso Scale Diagnostics, Gaithersburg, MD.
RNA isolation and real-time PCR
Total RNA was extracted from islets using the RNEasy micro kit (Qiagen, Hilden, 
Recordings of [cAMP] pm and plasma membrane PtdIns(3,4,5)P 3
Measurements of fluorescence from the CFP/YFP-based [cAMP] pm reporter or the GFP-based PtdIns(3,4,5)P 3 sensor were performed with total internal reflection fluorescence (TIRF) microscopy using either a custom-built prism-based system (22) or an objective-based setup (23) . The prism-type TIRF setup was built around an E600FN upright microscope (Nikon Corp, Tokyo, Japan). A helium-cadmium laser ] i values calculated as previously described (30) . Fluo-5F-loaded islets were imaged using the objective-based TIRF system described above for the PtdIns(3,4,5)P 3 measurements.
Data analysis
Image analysis was made using MetaFluor (Molecular Devices). [cAMP] [cAMP] pm elevation was unaffected (Fig. 1B-F) . The palmitate treatments caused modest, but significant (P<0.01 at 3:1; P<0.001 at 6:1) increases of INS1E-cell apoptosis (Fig. 1G) .
Similarly, mouse β-cells in intact islets responded to an increase of the glucose concentration from 3 to 20 mmol/L with shortly delayed and pronounced [cAMP] pm elevation, often with oscillations with frequencies in the 0.09-0.27/min range ( Fig.   2A ). Addition of 100 nmol/L GLP-1 triggered stable [cAMP] pm elevation, which was counteracted by 5 µmol/L adrenaline used to confirm the β-cell identity (23) (Fig.   2A ). After 48 h exposure to 0.5 mmol/L palmitate in 1% BSA, the glucose-induced (Fig. 2C ). GLP-1 (100 nmol/L) induced sustained [cAMP] pm elevation, which was reversed by 5 µmol/L adrenaline (Fig. 2C) . Like in INS1E-and mouse β-cells, 48 h exposure to palmitate selectively suppressed the glucose-induced [cAMP] pm elevation (P<0.001) (Fig. 2D-E) .
Short palmitate treatment does not affect glucose-and GLP-1-induced [cAMP] pm signaling
Acute exposure of mouse islet β-cells to 0.5 mmol/L palmitate (1% BSA) in the presence of 3 mmol/L glucose sometimes resulted in transient [cAMP] pm elevation (7 out of 15 cells; Fig. 3A ). However, there was no effect when palmitate was added in the presence of 20 mmol/L glucose or 100 nmol/L GLP-1 (Fig 3B-C) . Likewise, there were no differences in glucose-or GLP-1-induced cAMP signaling after 1 h preincubation with palmitate ( Fig. 3D-F) . The mechanism behind the modest [cAMP] ] i (Fig. 4E-F,   I ).
Palmitate impairs glucose-induced pulsatile insulin secretion
To investigate if the compromised [cAMP] pm signaling was associated with impaired insulin secretion, we monitored the time-course of insulin secretion from individual cells within intact islets by detecting the lipid PtdIns(3,4,5)P 3 , which is formed in the plasma membrane following autocrine insulin receptor activation (21) . Control mouse and human islet β-cells responded to glucose with pronounced PtdIns(3,4,5)P 3 oscillations reflecting pulsatile insulin secretion (Fig. 5A-B) . The glucose response was almost abolished after 48 h palmitate treatment, and the cells showed only a transient increase or minute stable PtdIns(3,4,5)P 3 elevation without oscillations ( Fig.   5C -E). The reduced response was not due to impaired insulin signaling, since exogenously added insulin evoked PtdIns(3,4,5)P 3 elevation (Fig. 5C-E) . Consistent with deficient cAMP production underlying the impaired secretory response to glucose the fraction of cells responding with increased PtdIns(3,4,5)P 3 was doubled and the response amplitude several-fold increased when 20 mmol/L glucose was added in the presence of the AC activator forskolin (Fig. 5E-F) . The palmitateinduced suppression of glucose-induced insulin secretion was confirmed by measurements of insulin release from batch-incubated islets using a conventional immunoassay (Fig 5G) . The results also demonstrate that 1 nmol/L GLP-1 restores insulin secretion to similar levels as in the control (Fig 5G) .
Reduction of AC expression underlies palmitate impairment of glucose-induced cAMP production
Next, the expression of ACs and phosphodiesterases (PDEs), synthesizing and degrading cAMP, respectively, was evaluated by real-time PCR. After 48 h palmitate treatment of mouse islets, AC9 mRNA was reduced to 70% (P<0.01) but there were no changes in expression of AC1, AC3, AC5, AC6, AC8 (Fig. 6A ) or any of the tested PDEs (PDE1C, -3B, -4A and -8B; Fig. 6B ). In human islets, AC5 was reduced and AC8 was increased, while other ACs did not show significant alterations in mRNA expression (Fig. 6C) . The importance of AC9 for glucose-induced [cAMP] pm signaling in mouse β-cells was investigated by siRNA-mediated knock-down in MIN6 cells. After 48 h treatment with siRNA, AC9 mRNA was reduced to 50%, and only 21% of the cells responded to glucose with [cAMP] pm oscillations as compared to 91% in control-siRNA-treated cells (Fig. 6D-E) . The average glucose-induced [cAMP] pm response was thus significantly suppressed after AC9 knockdown ( Fig. 6F; P<0.001). Also the GLP-1-induced [cAMP] pm elevation was reduced, but not to the same extent ( Fig. 6F; P<0 .05). The reduced AC9 expression was accompanied by impaired insulin secretion. When evaluating glucose-induced PtdIns(3,4,5)P 3 formation, the initial 10 min of the glucose response was unaffected, whereas the subsequent sustained response was significantly reduced in siRNA-treated cells ( Fig   6G-H, K) . The lower insulin secretion most likely reflected the deficient cAMP production, since the response was restored by addition of 1 mmol/L 8-Br-cAMP ( Fig   6I-K) .
DISCUSSION
Deleterious effects of FFAs on β-cell function are well documented (5) (6) (7) (8) , but the mechanisms underlying the defective insulin secretion are not well understood. In the present study we show that inhibition of glucose-induced cAMP production in β-cells contributes to impaired insulin secretion after long-term exposure to palmitate.
With the advent of techniques to monitor cAMP dynamics in single-cells, increasing evidence indicates that intracellular cAMP elevation is an integral part of glucose stimulus-secretion coupling in β-cells (21, 32, 33) . Measurements in the subplasma membrane space of both clonal and primary mouse β-cells have shown that cAMP often oscillates and contribute to pulsatile release of insulin (21) (22) (23) . The present data show that glucose triggers cAMP oscillations also in human β-cells.
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Increases of cAMP amplify insulin secretion both via protein kinase A (PKA) and the guanine nucleotide exchange factor Epac. The cAMP effectors act at multiple levels to influence the activity of various ion channels and other proteins involved in signaling and exocytosis (34) (35) (36) (37) (38) (39) (40) . It is therefore not surprising that deteriorated glucose-induced cAMP generation results in impaired insulin secretion.
The observation that glucose-induced cAMP signaling is suppressed in palmitatetreated cells is consistent with previous findings that the secretory defect involves a late step in stimulus-secretion coupling (16 β-cell dysfunction induced by long-term exposure to palmitate typically culminates in apoptotic cell death (7, 12) . However, our relatively mild treatment regime had little effects on cell viability, indicating that the observed signaling defect represents an early event in the lipotoxic process causing β-cell failure. Importantly, the deficient glucose-induced cAMP production did not reflect a general deterioration of the cAMP signaling system since the cells responded normally to GLP-1. cAMP has been found to protect from apoptosis in many cell types, including palmitate-induced apoptosis in insulin-secreting cells (50) . Impaired glucose-induced cAMP generation might therefore not only explain defective insulin secretion but also contribute to the general β-cell dysfunction after chronic exposure to palmitate. 
